Last reviewed · How we verify

Reiferon retard — Competitive Intelligence Brief

Reiferon retard (Reiferon retard) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alfa-2a (long-acting/sustained-release formulation). Area: Oncology, Virology/Infectious Disease.

marketed Interferon alfa-2a (long-acting/sustained-release formulation) Type I interferon receptor (IFNAR) Oncology, Virology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Reiferon retard (Reiferon retard) — MinaPharm Pharmaceuticals. Reiferon retard is a long-acting formulation of interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Reiferon retard TARGET Reiferon retard MinaPharm Pharmaceuticals marketed Interferon alfa-2a (long-acting/sustained-release formulation) Type I interferon receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alfa-2a (long-acting/sustained-release formulation) class)

  1. MinaPharm Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reiferon retard — Competitive Intelligence Brief. https://druglandscape.com/ci/reiferon-retard. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: